News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Subscribe To Our Newsletter & Stay Updated
